DS
VBIO

DRW Securities’s Valion Bio VBIO Stock Holding History

DRW Securities’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,935
Closed -$156K – 1695
2025
Q3 		$156K Buy
+53,935
New +$186K ﹤0.01% 1126

Other funds holding VBIO

MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DRW Securities's VBIO Position: Q4 2025 in Review

DRW Securities sold out of Valion Bio (VBIO) in Q4 2025, closing a stake of 53,935 shares — an estimated $156K sold.

DRW Securities first reported a position in VBIO in Q3 2025 and held it in 1 quarter. The position peaked at $156K in Q3 2025. 7 funds tracked by Wall St. Rank hold VBIO as of Q4 2025.

  • DRW Securities reported no remaining Valion Bio position as of Q4 2025 after selling out during the quarter.
  • DRW Securities sold 53,935 Valion Bio shares in Q4 2025, an estimated $156K.
  • DRW Securities first reported a position in Valion Bio in Q3 2025 and held it in 1 quarter.
  • DRW Securities's Valion Bio position peaked at $156K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Valion Bio as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.